knowledge -WSS

knowledge

author：fashion 2025-09-29 20:53:01 - browse：26213

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： How one patient went off dialysis — and others can too

focus

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

New weight loss drugs vying to be the next Wegovy or Mounjaro

FDA advisers vote against ALS treatment from BrainStorm

White House touts steps to stem shortages of cancer treatments

Hospitals consider fixing cancer drug shortages on their own

FDA advisers vote against ALS treatment from BrainStorm

hotspot

knowledge

explore

Jerome Adams on the need for new antivirals for Covid

Mindstrong's demise and the future of mental health care

The high cost of giving birth even with insurance

Pig kidney works a record two months in donated body

Continuity nursing helped my family in our darkest PICU moments

Walmart eyes Medicare Advantage provider ChenMed

State Dept. review finds Biden bears some blame for Afghanistan failures

A common UTI test for kids haunts adults as a traumatic 'nightmare'

BioMarin wins approval for gene therapy to treat hemophilia A

Inequities make cancer less preventable for women: report

focus

How housing is health care on Long Island

Why do women spend more than men on medical expenses?

Acelyrin, a rare IPO success, stumbles in its first big test

FDA advisers vote against ALS treatment from BrainStorm

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Diverse clinical trials: Why aren’t we there yet?

focus

focus

focus

hotspot